Hims & Hers Replaces Juniper with Hers in Australia
US telehealth giant consolidates Eucalyptus acquisition by rolling out full women's health platform.
1Consolidating Eucalyptus Takeover
US telehealth platform Hims & Hers is officially launching its women’s brand, Hers, in Australia. This move retires local weight-loss brand Juniper following the company's $1.6 billion acquisition of Sydney start-up Eucalyptus. Men’s health brand Pilot completed a similar transition to Hims earlier in August.
2Expanding Clinical Scope
While Juniper focused primarily on weight management, Hers introduces dedicated tracks for hair loss and menopause. Former Eucalyptus CEO Tim Doyle noted that transitioning to the global brand will modernize operations, even if some initial friction occurs among customers accustomed to the legacy Australian consumer identity.
3Preserving Local Care Teams
Existing Juniper subscribers will maintain continuity with Australian practitioners, care teams, treatment protocols, and pricing. Gus Wood leads the local division as general manager alongside chief medical officer Matt Vickers, as Eucalyptus retains its 250-person domestic workforce to support ongoing international expansion.
4Cruise AI Engineering Integration
Hims & Hers recruited applied AI engineers from autonomous vehicle startup Cruise to build clinical workflow and coaching infrastructure. The Australian operation is already deploying these tools, leveraging large language models to triage patient inquiries and hand off complex clinical decisions directly to human medical providers.
5Australian Pricing and Protocols
The Australian service will prescribe on-label, TGA-approved drugs like Wegovy and Mounjaro starting at $349 monthly, following national bans on compounded GLP-1 alternatives. Menopause consultations begin at $99 with monthly treatments from $17, alongside hair loss initial assessments priced at $24.99.
6Direct Marketing Regulatory Constraints
Unlike its US playbook featuring Super Bowl campaigns, Hims & Hers faces strict Australian bans on direct-to-consumer prescription advertising. Consequently, Hers is shifting local marketing toward symptom education rather than specific pharmaceutical promotion, adapting customer acquisition strategies to comply with strict domestic therapeutic goods legislation.
7Medical Establishment Pushback
The Royal Australian College of General Practitioners cautioned that subscription-based prescribing models risk prioritizing financial incentives over longitudinal care. RACGP leadership emphasized that GLP-1 therapies and hormone treatments require comprehensive monitoring, warning against fragmented digital health interventions that bypass holistic medical histories.
8Anticipating National Telehealth Standards
In response to clinical scrutiny, Hers allows sharing consultation notes with primary GPs upon patient consent. Leadership actively supports impending regulatory standards expected within twelve months, aiming to formalize digital health compliance as Hims & Hers prepares further expansion into Europe and South America.
Original article: WA Today - Technology — Hims & Hers Replaces Juniper with Hers in Australia